Men Favor Prostate Cancer Test Despite Task Force Recommendation

Published Online: Monday, September 16, 2013
Follow Pharmacy_Times:
In a recent study, a majority of men reported they still wanted to receive prostate-specific antigen testing, despite recommendations by the US Preventive Services Task Force (USPSTF) against the test.

The study, published in the August 2013 issue of the American Journal of Preventive Medicine, surveyed 1089 men aged 40 to 74 years, without a history of prostate cancer, on their awareness and response to the October 2011 USPSTF draft recommendation against prostate-specific antigen testing. The survey was conducted online from November 22 to December 2, 2011, and responses were analyzed in March 2012.

After reviewing the recommendation, 62% of participants understood the reasons why the recommendation was made and agreed with it. Only 13% of the men, however, planned to follow the recommendation in the future, and 54% planned to have a prostate-specific antigen test, regardless of the recommendation. The remaining 33% of participants were undecided on whether to follow the recommendation or not. The results also indicated that African Americans, individuals with higher income, those who were worried about developing prostate cancer, and those who had already received a prostate-specific antigen test within the past 2 years were the most likely to report that they would ignore the USPSTF recommendation.

The USPSTF currently recommends against prostate-specific antigen testing, as the risks, which include false-positive results, outweigh the benefits.

Related Articles
Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
A vaccine therapy that stimulates the body’s own immune defenses is safe to give to prostate cancer patients early in the disease’s progression, a recent study found.
Researchers have developed a personalized genetic test that can accurately predict the risk for recurrence in prostate cancer patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$